Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 548 of 5804
-
New combo therapy aims to stop bladder cancer return after surgery
Disease control OngoingResearchers are looking for new ways to treat people with high-risk muscle-invasive urothelial carcinoma (MIUC). Urothelial carcinoma is a type of bladder cancer that begins in cells that line the inside of the bladder and other parts of the urinary tract, such as part of the kid…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Could a One-Time cell infusion tame lupus and other autoimmune diseases?
Disease control Recruiting nowThis is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate-to-severe active systemic lupus erythematosus (SLE) with or withou…
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Proton therapy takes on rare chest cancer in major trial
Disease control Recruiting nowPhase III randomised-controlled trial for patients with unilateral malignant pleural mesothelioma (MPM).
Phase: NA • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Immune drug aims to wipe out prostate cancer in new trial
Disease control Recruiting nowThe purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11 works by activating the immune system to find and kill cancer cells. Researchers will look at whether this treatment ap…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug cocktail aims to outperform standard lung cancer therapy
Disease control OngoingThis is a Phase II/III, randomized, open-label, active-controlled, multicenter study to compare intravenous uliledlimab combined with toripalimab, toripalimab monotherapy, and pembrolizumab monotherapy in patients with previously untreated locally advanced unresectable or metasta…
Phase: PHASE2, PHASE3 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Can a Patient's own immune cells beat childhood cancers that Won't quit?
Disease control OngoingThis study is planned to test the safety and tolerability of the TIL regimen. The study will also test how well TIL fights cancer. The study will enroll children, teenagers, and young adults with solid tumors that have returned or are not responding to treatment for whom no effec…
Phase: PHASE1 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Immunotherapy combo may boost liver cancer ablation outcomes
Disease control OngoingThis project is a Phase 2 trial testing the safety and efficacy of treatment with Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting in patients with BCLC A HCC treated by by percutaneous ablation (PA) procedure in a curative intent. DUMELEP is a Multicent…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo treatment aims to boost recovery after severe brain bleed
Disease control Recruiting nowThe LD-ITUK is a multicenter, prospective, randomized, double-blind, blind endpoint, placebo-control design trial. All eligible patients with the diagnosis of severe aSAH will be randomly assigned to the treatment group or the placebo group. Patients in the treatment group will r…
Phase: PHASE4 • Sponsor: Second Affiliated Hospital of Nanchang University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New heart failure drug JK07 enters Mid-Stage trial
Disease control OngoingThis is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure. There will be 2 cohorts in this study: Cohort 1: Heart failure (HF) participants with lef…
Phase: PHASE2 • Sponsor: Salubris Biotherapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could a Vitamin-Like pill slow Alzheimer's? new trial seeks answers
Disease control OngoingThe purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.
Phase: PHASE2 • Sponsor: Alzheimer's Disease Cooperative Study (ADCS) • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New nasal spray could tame stage fright in social anxiety
Symptom relief OngoingThis U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxi…
Phase: PHASE3 • Sponsor: VistaGen Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC
-
New hope for kids with rare immune cell cancer: drug trial launches
Disease control Recruiting nowThis phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not re…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New hope for chronic hive sufferers: phase 3 drug trial shows promise
Symptom relief OngoingA Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TLL-018 in Participants With Moderate-to-Severe Chronic Spontaneous Urticaria (CSU) With Inadequate Controll to Second Generation H1-antihistamines.
Phase: PHASE3 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
A Web-Based program aims to curb sexual violence on Campus—Will a nudge make it stick?
Prevention Recruiting nowThis project, SCALE, will be the first to compare lower-intensity (standard) and higher-intensity implementation strategies to deliver GlobalConsent-an efficacious web-based sexual violence prevention program-to men attending seven universities across Vietnam. Following a rigorou…
Phase: NA • Sponsor: Emory University • Aim: Prevention
Last updated Jul 25, 2026 00:00 UTC
-
New combo vaccine study: COVID-19 and flu shot together in one visit
⭐️ VACCINE ⭐️ CompletedThis is a multicenter, observer-blind, randomized, controlled phase 3 study to evaluate the immunogenicity, reactogenicity, and safety of an investigational self-amplifying RNA COVID-19 vaccine (ARCT-2303) administered concomitantly with quadrivalent influenza vaccines or standal…
Phase: PHASE3 • Sponsor: Arcturus Therapeutics, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:03 UTC
-
New hope for rare childhood cancer: drug cocktail aims to shrink tumors and prevent return
Disease control Recruiting nowThe study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk * To estimate the 3-year event-free survival for intermediate-risk patients treated with ifosfamide, doxorubicin, pazopanib, surgery, and maintenance pazopanib, wit…
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for aggressive breast cancer: immune combo shows promise
Disease control OngoingThis is a phase II study, preceded by a safety run-in, with two independent cohorts (cohort A in early Triple Negative Breast Cancer (TNBC) patients and cohort B in late in metastatic TNBC patients) designed to evaluate the efficacy of atezolizumab, tiragolumab and chemotherapy.
Phase: PHASE2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New immunotherapy cocktails aim to fight colorectal cancer in the liver
Disease control Recruiting nowThe goal of this clinical trial is to to learn about different combinations of immunotherapy in patients with colorectal cancer whose cancer has spread to their liver and are planning to have surgery to remove tumor metastases from their liver. The main questions it aims to answe…
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Immune cell injection takes on Hard-to-Treat leukemia
Disease control Recruiting nowThis is an open-label clinical study: phase Ia is the dose-escalation part, and phase Ib is the dose-expansion part. The phase Ia study is to evaluate the safety, tolerability, recommended phase II dose, pharmacokinetics, immunogenicity and preliminary efficacy of IBR733 cell inj…
Phase: PHASE1 • Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo shot CagriSema shows promise for diabetes and weight loss
Disease control CompletedThis study will look at how much CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") tha…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC